Laurence Buisseret, Director of the Medical Oncology Department at Institut Jules Bordet, shared a post on LinkedIn:
“As clinicians, we sometimes focus on efficacy first – but patient-reported outcomes (PROs) remind us how crucial it is to preserve quality of life (QOL) when implementing new treatments
Excellent presentation by Evandro de Azambuja showing that SG + pembrolizumab maintained overall QOL in patients in 1L with PD-L1+ mTNBC, with improvements across emotional, physical, and role functioning, and less pain and insomnia compared to chemo + pembro.
While symptoms like nausea or diarrhea increased, they were manageable and consistent with the known safety profile.
These findings highlight that PROs and QOL should be systematically included in clinical trials – they offer invaluable insights into how patients truly experience treatment and help us make better-informed clinical decisions.”
You can also read:
ESMO 2025 Day 1 Highlights Not to Miss
ESMO 2025 Day 2 Highlights Not to Miss
ESMO 2025 Day 3 Highlights Not to Miss
ESMO 2025 Day 4 Highlights Not to Miss
